Shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.50.
A number of analysts have recently commented on GANX shares. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, July 1st. BTIG Research reaffirmed a “buy” rating and set a $5.00 target price on shares of Gain Therapeutics in a research note on Tuesday, August 11th. Oppenheimer reaffirmed an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Weiss Ratings cut shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Finally, Roth Capital reissued a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th.
Check Out Our Latest Analysis on GANX
Gain Therapeutics Price Performance
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. As a group, equities research analysts forecast that Gain Therapeutics will post -0.5 EPS for the current fiscal year.
Institutional Trading of Gain Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sprott Inc. bought a new stake in Gain Therapeutics during the fourth quarter worth approximately $39,000. Commonwealth Equity Services LLC bought a new position in shares of Gain Therapeutics in the fourth quarter valued at $41,000. Two Sigma Securities LLC acquired a new stake in shares of Gain Therapeutics during the 2nd quarter valued at $26,000. Millennium Management LLC acquired a new stake in shares of Gain Therapeutics during the 4th quarter valued at $45,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Gain Therapeutics during the 4th quarter worth $47,000. 11.97% of the stock is currently owned by institutional investors.
Gain Therapeutics Company Profile
Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.
Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.
Featured Stories
- Five stocks we like better than Gain Therapeutics
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
